Today, EvidentIQ, a leading clinical data science group and Keyrus Life Science, the Connected Contract Research Organization (C²RO), announced the signing of their partnership. The synergy between both companies will improve automation, efficiency and agility in clinical research by leveraging new eClinical capabilities.

EvidentIQ, based in Hamburg, is a leading clinical data science group, offering state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA, RWE).

Keyrus Life Science, operating across Europe and North America, connects CRO expertise, life data science and digital enablement to fully leverage both clinical research ecosystems and real-world evidence to help organizations shape better their clinical research trial strategies.

“I’m very proud to be able to announce today the formation of a strategic partnership between EvidentIQ and Keyrus Life Science. I strongly believe that it will transform the industry and create significant value for our customers as they will benefit from receiving industry leading eClinical technology, Real World Evidence and a world-class, full service model on one hand.” says Andreas Weber, CEO at EvidentIQ. 

“Thanks to this partnership, Keyrus Life Science and EvidentIQ will be able to digitally empower and operate clinical research on a new level, offering life science companies the capability to access enhanced reactivity, flexibility and get the full value from their data in the development of new drugs and therapies” states Michael Attlan, VP Life Science at Keyrus, “This synergy and the complementary offerings between our two companies are both key success factors in delivering practical and efficient solutions for our clients in clinical research”.

About Keyrus Life Science

With more than 25 years of experience, Keyrus Life Science makes data matter to address the biggest clinical challenges for clients around the globe to enable long-term success. As part of the Keyrus Group, we connect CRO expertise, life data science and digital enablement to improve clinical trial efficiency and agility, to the utmost benefit of society and human health. As an innovation-centric company by design, we anticipate the future health needs in clinical research and uncover new solutions and technologies to develop faster the cures of tomorrow. With the help of the most advanced partners in the clinical research domain, we provide full services to optimize patient recruitment and engagement, to leverage insights from data, and to unlock new horizons for personalized therapeutic approaches.

For more information, visit https://keyruslifescience.com

Über die EvidentIQ Group GmbH

EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end to end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio such as patient recruitment, patient engagement media and a host of RWE late phase solutions EvidentIQ significantly helps customers optimize HTA submissions, pricing and reimbursement needs.

EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including US, Germany, France, UK, Italy, Japan and China.

Firmenkontakt und Herausgeber der Meldung:

EvidentIQ Group GmbH
Rathausmarkt 5
20095 Hamburg
Telefon: +49 (89) 4522775000
Telefax: +49 (89) 4522775900
https://evidentiq.com

Ansprechpartner:
Andreas Weber
CEO
E-Mail: andreas.weber@evidentiq.com
Für die oben stehende Story ist allein der jeweils angegebene Herausgeber (siehe Firmenkontakt oben) verantwortlich. Dieser ist in der Regel auch Urheber des Pressetextes, sowie der angehängten Bild-, Ton-, Video-, Medien- und Informationsmaterialien. Die United News Network GmbH übernimmt keine Haftung für die Korrektheit oder Vollständigkeit der dargestellten Meldung. Auch bei Übertragungsfehlern oder anderen Störungen haftet sie nur im Fall von Vorsatz oder grober Fahrlässigkeit. Die Nutzung von hier archivierten Informationen zur Eigeninformation und redaktionellen Weiterverarbeitung ist in der Regel kostenfrei. Bitte klären Sie vor einer Weiterverwendung urheberrechtliche Fragen mit dem angegebenen Herausgeber. Eine systematische Speicherung dieser Daten sowie die Verwendung auch von Teilen dieses Datenbankwerks sind nur mit schriftlicher Genehmigung durch die United News Network GmbH gestattet.

counterpixel